MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202611061593 A) filed by Ms. Shivani Pannu; and Dr. Inderjeet Verma on May 14, 2026, for Novel Tofacitinib-Based Liposomal And Ethosomal Gel Formulations For Transdermal Rheumatoid Arthritis Therapy.
Inventors include Ms. Shivani Pannu; and Dr. Inderjeet Verma.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: The present invention The present invention relates to a topical vesicular gel formulation of tofacitinib for localized rheumatoid arthritis therapy. The formulation comprises tofacitinib encapsulated in lipid-based nanovesicles selected from liposomes, ethosomes, or a combination thereof, uniformly dispersed in a Carbopol-based gel matrix. The liposomal vesicles comprise phospholipid and cholesterol, while the ethosomal vesicles comprise phospholipid, cholesterol, ethanol, propylene glycol, and aqueous phase. The nanovesicles have nanoscale particle size, improved drug entrapment, and spherical morphology. The gel matrix comprises Carbopol 940, triethanolamine, glycerin, water, and optionally propylene glycol, providing suitable viscosity, spreadability, pH, and physical stability. The formulation enhances skin permeation and sustained localized delivery of tofacitinib compared with raw drug. Ethosomal gel provides superior permeation due to ethanol-mediated stratum corneum fluidization and vesicle deformability. The invention provides a stable, patient-friendly topical formulation useful for reducing localized inflammation in rheumatoid arthritis while minimizing systemic exposure. (Accompanied Figure No. 1-4)
Disclaimer: Curated by HT Syndication.
